ELECTRONIC FILING

Attorney Docket No.: 9516-086-999

CAM No.: 501872-999085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jerome B. Zeldis Confirmation No.: 9742

Application No.: 10/534,324 Group Art Unit: 1612

Filed: February 24, 2006 Examiner: Sznaidman, Marcos L.

For: METHODS OF USING AND COMPOSITIONS

COMPRISING SELECTIVE CYTOKINE

INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE

DISEASES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

		**			
1.	Enclosures accompanying this Information Disclosure Statement are:				
	1a.	A list of all patents, publications, applications, or other information submitted for consideration by the office.			
	1b.	A legible copy of:			
		Each publication or that portion which caused it to be listed on the PTO-1449;			
including the claims, and any drawing of the application which caused it to be listed on the		For each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion that have been checked to be unavailable at the USPTO's private PAIR system;			
		An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report;			
		Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications;			
		All other information or portion which caused it to be listed on the PTO-1449.			
	lc.	Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and U.S. patent application publications are not submitted herewith unless required by the office.			
	1d.	Pursuant to 1287 OG 163, copies of cited pending unpublished applications that			

are available at the USPTO's private PAIR system are not submitted herewith.

2.		Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);				
		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;				
		☐ Before the mailing of the first Office action on the merits;				
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.				
3.	under 3	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.				
		(Check either Item 3a or 3b)				
	3a.	☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.				
	3b.	The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:				
		enclosed.				
		to be charged to Jones Day Deposit Account No. 50-3013.				
		(Item 3b to be checked if any reference known for more than 3 months)				
4.	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.					
	The Certification Statement in Item 5 below is applicable.					
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed.				
		to be charged to Jones Day Deposit Account No. 50-3013.				
5.	\boxtimes	Certification Statement (applicable if Item 3a or Item 4 is checked):				
	(Check either Item 5a or 5b)					
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.				
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.				
	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not				

		received by any ind days prior to the filing	ividual designated in 37 C.F.R. §1.56(c) more ng of this information disclosure statement.	than thirty		
6.	This application is a		ontinuation application under 37 C.F.R. §1.53(b) or (d).			
		(Check app	ropriate Items 6a, 6b and/or 6c)			
	6a.	6a. A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurre filed herewith.				
	6b.	No. , filed on	ns listed on Form PTO-1449 from prior applie , of which this application claims priori being submitted pursuant to 37 C.F.R. §1.98	ty under 35		
	6c.	Copies of the public prior application Ser	ations listed on Form PTO-1449 were not pre ial No. , filed on , and are provid	•		
7.	This is a Supplemental Information Disclosure Statement. (Check Item 7a)					
	7a.		nformation Disclosure Statement under 37 C. rmation Disclosure Statement filed on Augus			
8.	In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:					
		(C	heck Item 8a, 8b, or 8c)			
	8a. Satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.					
	8b.	Set forth in the applie	eation.			
	8c.	Enclosed as an attach	ament hereto.			
9.		The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.				
10.	No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).					
			Respectfully submitted			
Date:	Febru	uary <u>3</u> , 2010	ghalil/Mon	52,042		
			Yeaksil Moon JONES DAY 222 East 41st Street New York, New York 10017-6702 (212) 326-3939	(Reg. No.)		